


September 5, 2013

ContraFect

MOLECULAR TREATMENTS  
FOR INFECTIOUS DISEASE



## ContraFect to Present at the 2013 Stifel Healthcare Conference

YONKERS, NY -- (Marketwired) -- 09/05/13 -- [ContraFect Corporation](#), developing biotherapeutics for life-threatening infectious diseases, today announced that Robert C. Nowinski, the Company's founder and chief executive officer and Julia P. Gregory, the Company's executive vice president and chief financial officer, will present a corporate overview at the 2013 Stifel Healthcare Conference in Boston, MA, on Thursday, September 12<sup>th</sup> at 8:35 AM ET. Dr. Nowinski and Ms. Gregory will discuss the Company's novel approach to drug resistant staph infections and clinical plans for its lead product, CF-301.

### ***About ContraFect:***

ContraFect Corporation is a biotechnology company pioneering the use of Lysins and Monoclonal Antibodies to treat life-threatening infectious diseases. ContraFect's initial products include agents to treat diseases such as MRSA (drug-resistant staphylococcus bacteria) and influenza. Its scientific strategy focuses on the use of combination therapies, where it believes that the company's products will overcome high rates of mutation and resistance observed in microbes.

### ***About the Stifel 2013 Healthcare Conference:***

The 2013 Healthcare Conference will address trends in biotechnology, healthcare, major and specialty pharmaceuticals, medical devices and senior housing. Over 1,000 investors and 150 companies are expected to attend this year. In addition to company presentations, Stifel will once again include physician panels, pairing their research analysts with both prominent members of the academic community and executives from leading companies.

### **Safe Harbor Statement**

This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including those associated with our ability to obtain additional funds, obtain and maintain all necessary patents and licenses, meet applicable regulatory standards and receive required regulatory approvals, manufacture or commercialize our products at reasonable costs and

compete with other products and market our products in a profitable manner. We assume no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

For more information, contact:

Barry Kappel, Ph.D., MBA

VP Business Development

Tel: 914-207-2300

E-Mail: [Email Contact](#)

or visit: [www.contrafect.com](http://www.contrafect.com)

Source: ContraFect Corporation